GeNeuro SA (GNRO.PA)
EUR 0.08
(6.38%)
EUR 0.08
(6.38%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.31 Million EUR | -44.72% |
| 2022 | 11.42 Million EUR | -8.06% |
| 2021 | 12.42 Million EUR | 19.02% |
| 2020 | 10.43 Million EUR | 12.19% |
| 2019 | 9.3 Million EUR | 66094.85% |
| 2018 | 14.05 Thousand EUR | -53.73% |
| 2017 | 30.36 Thousand EUR | -19.62% |
| 2016 | 37.78 Thousand EUR | 81.96% |
| 2015 | 20.76 Thousand EUR | -99.77% |
| 2014 | 9.05 Million EUR | 115.83% |
| 2013 | 4.19 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 FY | 6.31 Million EUR | -44.72% |
| 2023 Q4 | 6.31 Million EUR | 0.0% |
| 2023 Q2 | 12.2 Million EUR | 0.0% |
| 2022 FY | 11.42 Million EUR | -8.06% |
| 2022 Q4 | 11.42 Million EUR | 0.0% |
| 2022 Q2 | 16.01 Million EUR | 0.0% |
| 2021 Q2 | 7.29 Million EUR | 0.0% |
| 2021 Q4 | 12.42 Million EUR | 0.0% |
| 2021 FY | 12.42 Million EUR | 19.02% |
| 2020 FY | 10.43 Million EUR | 12.19% |
| 2020 Q4 | 10.43 Million EUR | 0.0% |
| 2020 Q2 | 13.07 Million EUR | 0.0% |
| 2019 FY | 9.3 Million EUR | 66094.85% |
| 2019 Q2 | 14.1 Million EUR | 0.0% |
| 2019 Q4 | 9.3 Million EUR | 0.0% |
| 2018 Q2 | 21.95 Thousand EUR | 0.0% |
| 2018 FY | 14.05 Thousand EUR | -53.73% |
| 2018 Q4 | 14.05 Thousand EUR | 0.0% |
| 2017 Q2 | 27.87 Thousand EUR | 0.0% |
| 2017 FY | 30.36 Thousand EUR | -19.62% |
| 2017 Q4 | 30.36 Thousand EUR | 0.0% |
| 2016 FY | 37.78 Thousand EUR | 81.96% |
| 2016 Q4 | 37.78 Thousand EUR | 0.0% |
| 2016 Q2 | 44.37 Thousand EUR | 0.0% |
| 2015 Q4 | 20.76 Thousand EUR | 0.0% |
| 2015 FY | 20.76 Thousand EUR | -99.77% |
| 2015 Q2 | 7.53 Million EUR | 0.0% |
| 2014 FY | 9.05 Million EUR | 115.83% |
| 2014 Q4 | 9.05 Million EUR | 0.0% |
| 2013 FY | 4.19 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | 57.084% |
| ABIVAX Société Anonyme | 327.06 Million EUR | 98.07% |
| Adocia SA | 24.95 Million EUR | 74.704% |
| Aelis Farma SA | 26.28 Million EUR | 75.979% |
| Biophytis S.A. | 11.93 Million EUR | 47.11% |
| Advicenne S.A. | 12.4 Million EUR | 49.118% |
| genOway Société anonyme | 31.84 Million EUR | 80.175% |
| IntegraGen SA | 8 Million EUR | 21.092% |
| Medesis Pharma S.A. | 1.92 Million EUR | -227.716% |
| Neovacs S.A. | 47.53 Million EUR | 86.719% |
| NFL Biosciences SA | 3.97 Million EUR | -58.99% |
| Plant Advanced Technologies SA | 14.91 Million EUR | 57.668% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -68.489% |
| Sensorion SA | 46.49 Million EUR | 86.422% |
| Theranexus Société Anonyme | 7.23 Million EUR | 12.778% |
| TME Pharma N.V. | 2.49 Million EUR | -153.428% |
| Valbiotis SA | 33.24 Million EUR | 81.013% |
| TheraVet SA | 7.53 Million EUR | 16.21% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | 82.103% |
| argenx SE | 4.11 Billion EUR | 99.846% |
| BioSenic S.A. | 9.55 Million EUR | 33.959% |
| Celyad Oncology SA | 16.28 Million EUR | 61.228% |
| DBV Technologies S.A. | 165.65 Million USD | 96.189% |
| Galapagos NV | 4.35 Billion EUR | 99.855% |
| Genfit S.A. | 173.87 Million EUR | 96.369% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | 86.76% |
| Innate Pharma S.A. | 184.19 Million EUR | 96.573% |
| Inventiva S.A. | 69.13 Million EUR | 90.869% |
| MaaT Pharma SA | 42.93 Million EUR | 85.295% |
| MedinCell S.A. | 36.94 Million EUR | 82.914% |
| Nanobiotix S.A. | 93.89 Million EUR | 93.277% |
| Onward Medical N.V. | 43.62 Million EUR | 85.53% |
| Oryzon Genomics S.A. | 106.9 Million EUR | 94.095% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | 92.292% |
| Oxurion NV | 6.55 Million EUR | 3.62% |
| Pharming Group N.V. | 426.33 Million EUR | 98.519% |
| Poxel S.A. | 4.82 Million EUR | -30.892% |
| GenSight Biologics S.A. | 9.08 Million EUR | 30.528% |
| Transgene SA | 45.21 Million EUR | 86.039% |
| Financière de Tubize SA | 1.92 Billion EUR | 99.671% |
| UCB SA | 15.53 Billion EUR | 99.959% |
| Valneva SE | 469.39 Million EUR | 98.655% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | 79.523% |